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We examined the selective pressure for, and the impact of, p53 inactivation during epithelial tumor evolution
in a transgenic brain tumor model. In TgT121 mice, cell-specific inactivation of the pRb pathway in brain
choroid plexus epithelium initiates tumorigenesis and induces p53-dependent apoptosis. We previously showed
that p53 deficiency accelerates tumor growth due to diminished apoptosis. Here we show that in a p531/2
background, slow-growing dysplastic tissue undergoes clonal progression to solid angiogenic tumors in all an-
imals. p53 is inactivated in all progressed tumors, with loss of the wild-type allele occurring in 90% of tumors.
Moreover, similar progression occurs in 38% of TgT121p53
1/1 mice, also with loss of at least one p53 allele and
inactivation of p53. Thus, the selective pressure for p53 inactivation, likely based on its apoptotic function, is
high. Yet, in all cases, p53 inactivation correlates with progression beyond apoptosis reduction, from dysplasia
to solid vascularized tumors. Hence, p53 suppresses tumor progression in this tissue by multiple mechanisms.
Previous studies of fibroblasts and hematopoietic cells show that p53 deficiency can be associated with chro-
mosomal instability, a mechanism that may drive tumor progression. To determine whether genomic gains or
losses are present in tumors that progress in the absence of p53, we performed comparative genomic hybrid-
ization analysis. Surprisingly, the only detectable chromosomal imbalance was partial or complete loss of
chromosome 11, which harbors the p53 gene and is thus the selected event. Flow cytometry confirmed that the
majority of tumor cells were diploid. These studies indicate that loss of p53 function is frequent under natural
selective pressures and furthermore that p53 loss can facilitate epithelial tumor progression by a mechanism
in addition to apoptosis reduction and distinct from chromosomal instability.
The p53 gene is mutated in at least 50% of human cancers,
including most tumor types (27, 35, 43). Although many pos-
sible mechanisms for p53 tumor suppression have been defined
for cultured cells, no mechanism has been fully established in
vivo. In cultured cells, p53 is activated in response to a variety
of cellular stress signals including DNA damage, aberrant pro-
liferation, hypoxia, and nucleotide deprivation (36, 50, 56).
Activation of p53 leads to either growth arrest or apoptosis, a
decision that appears to depend on the cell type and specific
stimulus (2, 22, 36, 65, 67). Thus, the in vivo signals for p53
tumor suppression and the mechanism by which p53 inactiva-
tion contributes to tumorigenesis are likely to vary depending
on the cell type and environment. Based on the known func-
tions of p53, there are several mechanisms by which p53 inac-
tivation could contribute to cancer. For example, p53 regulates
a G1 checkpoint in fibroblasts in response to DNA damage, a
response that requires transcriptional activation of the p53
target gene p21 (7, 14). In addition, p53 can arrest cells in G2,
possibly via transcriptional activation of 14-3-3 s (25) and/or
transcriptional repression of cdc2 and cyclin B1 (61). Impor-
tantly, Chk1 and Cds1/Chk2 kinases involved in replication and
DNA damage-induced G2 arrest have recently been shown to
phosphorylate p53 (9, 26, 58). The identification of a Cds1/
Chk2 mutation in a Li-Fraumeni syndrome family that lacks
p53 mutation supports the idea that Cds1/Chk2 and p53 func-
tion in a pathway for tumor suppression (3). Finally, p53 pre-
vents DNA endoreduplication in fibroblasts exposed to mitotic
spindle inhibitors (15) and has been implicated in centrosome
regulation (20). In the absence of p53, cultured fibroblasts
can be readily selected for gene amplification, indicating a
tendency for genetic instability upon p53 deficiency (38, 73).
These observations led to the “guardian of the genome” hy-
pothesis for p53 tumor suppression (32), which suggests that
p53 inactivation may contribute to tumorigenesis by facilitating
the propagation of genetically defective cells as a result of
checkpoint loss (23). Secondary mutations or chromosomal
changes that provide the cell a selective advantage would thus
facilitate tumorigenesis. Indeed, hematopoietic tissues from
p53-deficient mice contain a high percentage of aneuploid cells
(6, 21), the mice are predisposed to thymic lymphoma (17, 30),
and lymphomas are aneuploid (37, 64). However, the direct
contribution of p53-deficiency-induced genetic instability to
tumorigenesis has not been demonstrated in vivo.
Another mechanism by which p53 can suppress tumorigen-
esis involves the apoptotic response to aberrant proliferation
induced by oncogene expression or pRb inactivation. Many
studies have demonstrated that this response is p53 dependent
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(13, 28, 39, 41, 42, 47, 53, 68), indicating that developing tu-
mors could activate p53, thus establishing a selective pressure
for p53 inactivation leading to tumor cell survival. We previ-
ously demonstrated such a role for p53 in vivo using a trans-
genic mouse model that undergoes epithelial cell tumorigene-
sis in response to pRb pathway inactivation (60). In the choroid
plexus (CP) epithelium, p53 inactivation alone is inconsequen-
tial, as is the case for most mouse epithelial cells (17, 30).
However, cell-specific inactivation of the pRb pathway induces
aberrant proliferation and dysplastic growth, resulting in p53-
dependent apoptosis (see Fig. 1). A similar response occurs in
the lens (46) and retina (28) and in several cell types during
development (41, 42). In the brain tumor model, germ line p53
deficiency leads to significant acceleration of dysplastic tissue
growth due to an 85% reduction in apoptosis (60). Impor-
tantly, most human tumors harbor a defect in the pRb pathway
(70); thus, p53 and Rb pathway mutations frequently coexist
during the course of tumorigenesis. Hence, it is important to
understand the dynamic interplay between these aberrations
during tumor development. The dependency of tumor cell
apoptosis on p53 function suggests that selective pressure for
inactivation of the p53 pathway should be high in a developing
tumor. Such direct selection for p53 inactivation is unlikely to
result from a role in genome maintenance alone. However,
once a p53-deficient cell is selected based on survival, its prop-
agation in the absence of p53-dependent checkpoints could
result in genetic aberrations that may accelerate tumor pro-
gression. By this scenario, p53 inactivation would contribute to
tumorigenesis by multiple mechanisms. In the present report,
we test this hypothesis by exploring the evolution of developing
CP tumors in p53 heterozygous and wild-type backgrounds.
We assess the natural selective pressure for p53 inactivation
and the contribution of p53 inactivation to tumor progression.
In particular, we explore the possibility that chromosomal in-
stability drives tumor progression in tumors that evolve to a
p53-deficient state. The contribution of p53 inactivation to
tumor progression during the natural evolution of epithelial
tumors lacking the Rb pathway has not previously been ex-
plored.
MATERIALS AND METHODS
Mice. Generation, screening, and characterization of TgT121 transgenic mice
(B6D2) were described previously (54, 60). These mice harbor the T121 mutant
T-antigen gene under the control of the lymphotropic papovavirus transcrip-
tional signals, resulting in uniformly high levels of expression in the CP (10). The
T121 transgene encodes the first 121 amino acids of simian virus 40 (SV40) T
antigen and is capable of binding to the pRb family proteins but not to p53.
TgT121p531/2 and TgT121p532/2 mice were generated by crossing TgT1211/1 or
TgT1211/2 mice with p532/2 mice (C57BL6/J; Jackson Laboratories) (30). Ge-
notypes were identified by PCR analysis of tail DNA as described previously (60).
Mice were monitored regularly for the outward signs of a brain tumor, which
consist of cranial bulging and decreased activity. Mice were then sacrificed, and
tumors were either frozen at 280°C for nucleic acid analysis or fixed in 10%
formalin as described previously (54).
Histology and immunohistochemistry. To analyze tumor morphology and
development, mouse brains were cut into halves, fixed in 10% formalin, embed-
ded in paraffin, and sectioned for 10 successive layers at 50-mm intervals. A 5-mm
section from each layer was stained with hematoxylin and eosin for morpholog-
ical analysis (60). To measure the tumor size, the slide with the largest tumor
cross section was chosen for each sample, and the tumor area was measured
using the PAXit image capture and analysis system (MIS, Inc.). The tumor
volume was then calculated with the assumption that the tumor has the same
volume as a sphere with an equivalent cross-sectional area.
For CD31 immunostaining, sections were treated with 1 mg of trypsin/ml in
phosphate-buffered saline (PBS) for 10 min at 37°C and then blocked in 5%
normal rabbit serum (NRS) in PBS for 1 h at room temperature (RT). The
sections were incubated with anti-CD31 antibody (1:50 in PBS containing 5%
NRS; Pharmingen) overnight at 4°C. After three washes in PBS, slides were
incubated with biotin-conjugated secondary antibody (1:100 in PBS containing
2% NRS) for 30 min at RT. Slides were washed twice with TS buffer (50 mM
Tris-HCl [pH 7.6], 150 mM NaCl, 0.1% Tween 20) and incubated with avidin-
biotin-peroxidase–alkaline phosphatase reagent (Vector Laboratories) for 30
min. After two washes with TS buffer, slides were incubated with alkaline phos-
phate substrate (Vector Laboratories) for 10 min at RT, counterstained with
methyl green, and dehydrated in two changes of xylene. The blood vessel pattern
of dysplastic CP and tumors was evaluated by quantifying CD31-positive vessels.
For each brain sample, the numbers of blood vessels larger than 200 mm2 were
counted in fields with abundant blood vessels. Dysplastic CP and terminal tumors
from seven T121p531/2 mice each were evaluated; the averages and the standard
deviations of their blood vessel counts are represented in Fig. 3.
Loss-of-heterozygosity (LOH) analysis. To determine the status of the wild-
type p53 allele in terminal TgT121p531/2 tumors, semiquantitative PCR analysis
was performed. The wild-type p53 allele was amplified with primers directed
against exon 6 (X6.5; 59-ACAGCGTGGTGGTACCTTAT-39) and exon 7 (X7;
59-TATACTCAGAGCCGGCCT-39), while the p53 null allele was amplified
with primers directed against the neomycin gene contained within the targeted
locus (neo18; 59-CTATCAGGACATAGCGTTGG-39) and p53 exon 7. The
25-ml PCR mixture contained 0.2 mM concentrations of each of the four de-
oxynucleoside triphosphates, 2 mCi of [a-32P]dCTP (3,000 Ci/mmol), 0.8 mM
X6.5 and neo18, 1.6 mM X7, 0.5 U of Taq polymerase (Boehringer Mannheim),
and 100 ng of DNA template. PCR was performed for 25 cycles using the
following conditions: 1 min at 94°C, 2 min at 60°C, and 2 min at 72°C. PCR
products were resolved on an 8% polyacrylamide gel and quantified using a
PhosphorImager (Molecular Dynamics). In standardization assays, tail DNA
from a p531/2 mouse and a p532/2 mouse were mixed at ratios ranging from 1:2
to 1:50. The ratio of the product intensity to the template concentration was
graphed and resulted in a linear relationship. The ratio of wild-type allele
intensity in the control lane was normalized to 1.00. With the assumption that the
tumor was not likely to include more than 30% nontumor cells, an arbitrary 0.33
intensity ratio threshold was established for determining LOH. The normalized
ratio threshold is 0.20. If the ratio of the p53 wild-type signal to p53 null signal
was greater than 0.20, the p53 wild-type allele was considered to be retained; a
ratio of less than 0.20 indicated loss. Two independent PCR assays were per-
formed for each sample.
To determine the status of the wild-type p53 allele in terminal TgT121p531/1
tumors, quantitative real-time PCR analysis was performed. The conditions for
analysis of the p53 locus were provided by Lynda Chin and colleagues (Harvard
University). The primers for the p53 allele were 59-ATGGCCATCTACAAGA
AGTCACAG-39 and 59-ATCGGAGCAGCGCTCATG-39. The sequence of the
p53 probe was 59-ACATGACGGAGGTCGTGAGACGCTG-39. The primers
for the internal control b-actin gene were 59-AAGAGCTATGAGCTGCCTG
A-39 and 59-ACGGATGTCAACGTCACACT-39. The sequence of the b-actin
probe was 59-CACTATTGGCAACGAGCGGTTCCG-39. Each 25-ml reaction
mixture contained 50 ng of DNA template, 18 nM p53 primers, 80 nM b-actin
primers, 8 nM probe, and 12.5 ml of TaqMan Universal PCR Master Mix
(Applied Biosystems) containing AmpliTaq Gold polymerase, deoxynucleoside
triphosphates, and PCR buffer. The cycling conditions were 50°C for 2 min and
95°C for 10 min for 1 cycle and 95°C for 15 s and 60°C for 1 min for 40 cycles.
The reactions were performed using an ABI 7700 Sequence Detection system
(Applied Biosystems), and the data were analyzed using Sequence Detector 1.7
(Applied Biosystems) and standard protocols (http://www.appliedbiosystems
.com). The copy number of each sample was determined by calculating DDCt
based on the formula DDCt 5 [sample Ct(p53) 2 sample Ct(b-actin)] 2 [p531/1
control Ct(p53) 2 p531/1 control Ct(b-actin)], where Ct is the number of cycles
required to reach a threshold based on linear amplification. Analyses of standard
samples (L. Chin, Harvard University, personal communication) indicate that
copy numbers of 2, 1, and 0 are indicated by 22DCtn values of .0.6, 0.15 to 0.6,
and ,0.15, respectively. Standard samples analyzed along with experimental
samples confirmed the accuracy of these assignments.
In situ RNA hybridization. In situ hybridization was carried out as described
previously (48). For template preparation, pBS-KSp21 was digested with EcoRI
and BamHI. The antisense probe was generated by T7 transcription of an
EcoRI-linearized template, and the sense probe was produced by T3 transcrip-
tion of a BamHI-linearized template. Probes were labeled with [a-35S]UTP (5 3
104 cpm/ml) and hybridized to slides at 50°C overnight. Autoradiography was
performed at 4°C for 3 days. Sections were counterstained with 0.2% toluidine
blue and observed and photographed using dark-field microscopy.
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CGH. Comparative genomic hybridization (CGH) was performed essentially
as described elsewhere (16, 31). Tumor and normal tail DNA were labeled by
nick translation using fluorescein-12-dUTP (NEN) and Alex-568-5-dUTP (Mo-
lecular Probes), respectively. The optimum probe size was about 600 bp. Labeled
tumor and normal DNA (1 mg each) were coprecipitated and dissolved in 10 ml
of hybridization solution to obtain a final composition of 50% formamide, 10%
dextran sulfate, and 23 SSC (13 SSC is 0.15 M NaCl and 0.015 M sodium citrate
[pH 7.0]). The mixture was heated to 70°C for 15 min to denature the DNA and
was incubated at 37°C for 10 min. Normal mouse metaphase chromosomes pre-
pared from mouse embryonic fibroblasts were denatured at 70°C in 70% form-
amide–23 SSC for 4 min and dehydrated through graded ethanols. The hybrid-
ization mixture was added to the slides, coverslips were sealed with rubber
cement, and the slides were incubated at 37°C for 3 days. The slides were washed
in formamide and SSC as previously described (31) and stained with 0.1 mM
49,69-diamino-2-phenylindole (DAPI). Digital images of each fluorochrome were
obtained using a fluorescence microscope and a charge-coupled device camera.
The profiles of different fluorescence intensities and corresponding chromo-
somal losses and gains were analyzed using Vysis software (Applied Images Inc.).
The normalized average ratio of green to red (tumor/normal ratio) is 1.0. The
threshold of variability using normal samples was 0.8 to 1.2.
Flow cytometry. Brain tumor cells were isolated and stained as described (52).
Since normal CP is difficult to cleanly dissect in sufficient quantity, normal spleen
cells were used as a diploid control. Glass slides and 70-mm-pore-size cell strain-
ers (Becton Dickinson) were used to dissociate tumor and spleen cells. The cells
were washed with PBS, fixed in 70% ethanol, and stained with 25 mg of pro-
pidium iodide/ml containing 0.1 mg of RNase A/ml. Flow cytometry was carried
out using a FACScan cytometer (Becton Dickinson), and data were analyzed
with Cyclops software (Cytomation).
RESULTS
High rates of tumor progression in TgT121p53
1/2 and
TgT121p53
1/1 mice. In TgT121 transgenic mice, pRb and re-
lated proteins p107 and p130 (collectively referred to here as
pRbf) are inactivated in the CP by tissue-specific expression of
the truncated SV40 T antigen, T121 (see Materials and Meth-
ods). Disruption of the pRb pathway in CP induces slow-
growing dysplastic masses, resulting in death of the mice at an
average of 26 weeks (Fig. 1A) (60). Upon pRbf inactivation,
CP cells are induced to proliferate aberrantly (54), resulting in
the induction of p53-dependent apoptosis (Fig. 1B) (60). In a
p532/2 background, growth of the CP masses is accelerated
approximately sevenfold (50% survival time 5 4 weeks [Fig.
1A]) due to an 85% reduction in cell death, although masses
remain morphologically dysplastic (60). We previously showed
that TgT121p53
1/2 mice survive to an intermediate age (50%
survival time 5 11 weeks [Fig. 1]) and show morphological
signs of clonal tumor progression (Fig. 1B) (60). As expected,
apoptosis levels were significantly reduced in progressed tu-
mors. This could occur by direct p53 inactivation or by inacti-
vation of other genes in the relevant p53 pathway (if a linear
pathway is involved) or in parallel pathways with similar func-
tion. To determine the genetic basis for tumor progression and
the selective pressure for and the contribution of p53 inacti-
vation, we carried out a comprehensive developmental analysis
of tumor evolution.
To more fully characterize tumor progression in TgT121
p531/2 and TgT121p53
1/1 mice, the frequency, timing, and
morphological characteristics of tumor progression were ana-
lyzed. Step sections were examined at 50-mm intervals for each
brain. In 42 of 43 TgT121p53
1/2 mice analyzed beyond 6 weeks
of age, the CP showed evidence of focal progression from
dysplasia to solid tumors (Fig. 2; see also Fig. 4). Normal CP
appears as frond-like papillary structures extending from the
walls of lateral ventricles and the roofs of the third and fourth
ventricles. Each frond consists of a single uniform layer of
differentiated epithelial cells (Fig. 2A). TgT121p53
1/2 mice
younger than 6 weeks all showed only dysplastic changes in CP
(Fig. 2B). The nuclei in these lesions were crowded and elon-
gated with a high nuclear/cytoplasmic ratio, and the chromatin
was dense and coarse. The single-layer structure was disrupted
with multilayer regions (Fig. 2B, arrows), but the overall frond-
like structure of the CP was maintained. No morphologically
distinct tumor foci were observed prior to 6 weeks of age. In
contrast, TgT121p53
1/2 mice sacrificed at 6 to 8 weeks of age
showed emergence of focal tumors in addition to the preexist-
ing dysplasia. The foci were characterized by nodules of solid
tumor arising from the papillary, dysplastic CP cells (Fig. 2E).
Tumors were relatively small at this stage; 16 of 22 tumors
were smaller than 10 mm3, with an average volume of 1.1 6 2.0
mm3.
From 9 to 14 weeks, all TgT121p53
1/2 tumors became life
threatening. At this stage, tumor morphology was similar to the
previous stage, but the tumors were much larger (Table 1). The
large tumors possessed an extensive vasculature (Fig. 2D and
H, e.g., arrows), and necrotic foci were sometimes present
(data not shown). CD31 staining of blood vessels showed that
tumors contained approximately five times the density of en-
larged vessels of that of dysplastic CP (Fig. 3). Thus, tumor
progression was associated with promotion of angiogenesis. In
some regions, tumor cells displayed a perivascular orientation,
and thus, the tumors resembled poorly differentiated papillary
adenocarcinomas (Fig. 2D and H). In some terminally ill mice,
tumors spread into the subarachnoid space surrounding the
brain, but invasion into adjacent brain parenchyma was rare (2
of 21 mice). In summary, these studies showed that the prob-
ability of tumor progression in mice with a single functional
p53 allele was 100%. Furthermore, the event(s) responsible for
tumor progression appeared to occur within a predictable
time, with the earliest morphological signs of progression de-
tectable at 6 to 8 postnatal weeks (Fig. 4).
Tumor progression also occurred with a high frequency
in TgT121p53
1/1 mice, although the timing was much less
predictable (Fig. 4), consistent with the requirement for a
minimum of two stochastic genetic lesions to inactivate p53.
Emerging tumors could be classified into two distinct morpho-
logical types (arbitrarily referred to as types I and II). Type I
tumors were identical to those arising in TgT121p53
1/2 mice
(Fig. 2, compare panels E and F and panels H and I). Focal
tumors with this morphology were observed in 10% of mice 6
to 24 weeks old; at 25 to 43 weeks, 38% of mice harbored type
I tumors (Fig. 4). While morphologically identical to TgT121
p531/2 terminal tumors, these tumors were often smaller (Ta-
ble 1), possibly owing to the older ages at which they devel-
oped. For example, life-threatening hydrocephalus, which was
not present in TgT121p53
1/2 mice, developed in 31% of the
TgT121p53
1/1 mice with type I tumors.
Type II tumors were less compact and were characterized by
considerable nuclear polymorphism. Type II cells had a lower
nuclear/cytoplasmic ratio than did type I cells; the cytoplasm
was copious, and nuclei were often grossly enlarged (Fig. 2G).
Apoptotic cells were also evident (data not shown). While
apoptosis in type I tumors had dropped to 3.6% 6 0.2%,
compared to 12.6% 6 2.8% in dysplastic tissue, apoptosis in
type II tumors was at an intermediate level (6.8% 6 1.8%).
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Type II tumors were generally much smaller than type I tu-
mors, although a subset of tumors containing type II morphol-
ogy grew to larger sizes (Table 1). These larger tumors were
heterogeneous and contained regions of densely packed cells
intermixed with typical type II morphology. Type II foci were
first observed in 9-week-old mice and were present in 25% of
mice at 15 to 24 weeks and 56% of mice at 25 to 43 weeks.
Hydrocephalus developed in 70% of mice with type II tumors
and likely accounts for the life-threatening condition despite
the relatively smaller tumor size. In general, TgT121p53
1/1
mice developed either type I or type II tumors; of the 33 mice
analyzed with tumors, only 2 harbored both tumor types. Of
the terminally ill mice, 41% had type I tumors and 59% had
type II tumors.
p53 is inactivated in all type I tumors. To determine wheth-
er p53 inactivation was associated with tumor progression and
to assess the selective pressure for p53 inactivation, we exam-
ined TgT121p53
1/2 tumors for loss of the wild-type p53 allele.
Semiquantitative PCR was used to detect p53 wild-type and
null alleles (Materials and Methods). DNA isolated from ter-
minal TgT121p53
1/2 tumors was compared with tail DNA from
the same mice. Due to the presence of stroma and vasculature
in the tumor samples, a reduction of two-thirds or more in the
wild-type signal relative to the null signal was considered a loss.
A representative result is shown in Fig. 5A. Of 34 TgT121p53
1/2
tumors analyzed, 32 showed convincing loss of the wild-type
allele (Fig. 4B). All tumors retained the null allele, indicating
that gene loss was not due to random genetic instability. Thus,
FIG. 1. A pathway to tumor development. (A) Time of survival from brain tumors depends on p53 status. Mice were sacrificed when they
showed severely bulged crania and decreased activity. Histological examination confirmed the presence of CP masses in all mice. (Data are revised
from those presented in reference 60.) (B) The diagram depicts previously elucidated steps in T121-induced development of CP tumors. T121
induces proliferation of normally nondividing epithelial cells by inactivating the pRb family proteins pRb, p107, and p130. p53-dependent apoptosis
is then activated by a process requiring E2F1 (48). As shown in the present report, in a p53 heterozygous background, the selective pressure for
p53 inactivation is 100%, resulting in the focal development of solid vascularized tumors.
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the selective pressure for p53 loss during tumor progression
was extremely high, with 94% of tumors having specifically lost
the functional p53 allele.
To determine whether p53 function was also disrupted in the
tumors that retained the wild-type p53 allele and to determine
whether p53 loss occurred concomitantly with tumor progres-
sion rather than subsequently, we assessed p53 activity in situ.
As described previously, the p53 target gene p21 is transcrip-
tionally activated in CP upon T121 expression (48). In this
system, p21 expression is entirely dependent upon p53 activa-
tion, since it is undetectable in TgT121p53
2/2 CP (48) (Fig. 5B,
subpanels a to c). Furthermore, we have shown elsewhere
through genetic experiments that p21 is not required for p53-
FIG. 2. Tumor progression in T121p53
1/2 and T121p53
1/1 mice. Normal CP of a 3-month-old nontransgenic mouse (br, brain tissue). Cells con-
tain regularly sized and shaped nuclei with significant cytoplasm in a single layer forming a papillary architecture (A). Due to T121 expression, the
CP of young T121p53
1/2 (3 weeks) (B) and T121p53
1/1 (5 weeks) (C) mice appears dysplastic (dy) with nuclei of aberrant sizes and a high nuclear/
cytoplasmic ratio in most cells. The overall papillary organization of the tissue is retained; however, multilayered regions are present. The black arrow
indicates dysplastic cells, and the pink arrow indicates normal cells. Focal solid masses indicative of tumor (tu) progression are detectable by 6 to
8 weeks in all T121p53
1/2 mice (7-week-old mouse shown in panel E) and at various times beyond 7 weeks in some T121p53
1/1 mice (7-week-old
mouse shown in panel F). These focal tumors arise among the background of dysplastic CP. Solid vascularized tumors (designated type I) grow
rapidly and become life threatening by 12 weeks in all T121p53
1/2 mice (12-week-old mouse shown in panels D and H) and at 25 to 43 weeks in 38%
of T121p53
1/1 mice (38-week-old mouse shown in panel I). The red arrows in these figures indicate blood vessels. Tumors of distinct morphology
(type II) also arise in 59% of T121p53
1/1 mice (38-week-old mouse shown in panel G). Loosely organized cells within these masses often contain
copious cytoplasm and grossly enlarged nuclei. These tumors appear to grow slowly, since they do not reach the large sizes observed for type I tumors.
All slides were stained with hematoxylin and eosin. Each white bar represents 50 mm, and each black bar represents 200 mm.







1/2 I 14 26.2–268.1b .95.8 6 70.4b
T121p53
1/1 I 5 10.1–122.4 42.6 6 46.4
T121p53
1/1 II (a)c 12 0.4–5.0 2.1 6 1.4
T121p53
1/1 II (b)c 3 24.1–56.7 40.7 6 16.3
a Tumor volumes were measured based on area measurements in brain sec-
tions from terminally ill mice (see Materials and Methods).
b Many of the largest T121p531/2 tumors from the same brains were dissected
for DNA analysis and thus not measured.
c A subset of tumors with type II morphology was heterogeneous. These
tumors (type IIb) grew to larger sizes than those consisting of only type II
morphology (type IIa) and also contained regions of densely packed cells.
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dependent apoptosis in this system (C. Yin et al., unpublished
data). Thus, there should be no selective pressure for p21 loss
in the absence of p53 loss. In situ hybridization was used to
detect p21 transcripts in TgT121p53
1/2 CP in which both dys-
plasia and a progressed tumor were present (Fig. 5B, subpanel
d). p53 function, as indicated by the presence of p21 tran-
scripts, was clearly absent from the progressed tumor but was
present in the surrounding dysplastic regions (Fig. 5B, sub-
panel e). In addition, five of five terminal tumors that showed
p53 LOH had also lost p21 expression, indicating the consis-
tency of this assay in detecting p53 inactivation (Fig. 4B).
The two tumors that had retained the wild-type p53 allele by
LOH analysis showed loss of p21 transcripts, indicating that
the p53 pathway was functionally inactivated in 100% of pro-
gressed tumors (Fig. 4B). To assess the correlation between
p53 inactivation and tumor progression, brains with the earliest
detectable focal lesions were analyzed. Brains from all six
TgT121p53
1/2 mice analyzed at 6 to 8 weeks old showed clear
loss of p53 function in focal tumors with retention of function
in dysplastic regions (Fig. 4B). Thus, p53 inactivation was likely
causal in the progression of these tumors.
To determine whether type I tumors in TgT121p53
1/1 mice
showed similar loss of p53 function, we examined 11 tumors at
various stages. p21 in situ analysis again showed loss of p53
function in all type I tumors (Fig. 5B, subpanels f and g, and
4B). Consistent with results from TgT121p53
1/2 tumors, p53
activity was lost at an early stage when tumor foci were very
small (data not shown), indicating that loss of p53 is a rate-
limiting event in tumor progression. Real-time PCR analysis
showed that at least one p53 allele was lost in three of three
tumors analyzed (Table 2), suggesting that p53, and not an
upstream factor, was the target for inactivation. In contrast to
type I tumors, 11 of 11 TgT121p53
1/1 type II tumors analyzed
at both early and late stages retained p53 activity, and three of
these tumors analyzed for gene loss retained both wild-type
p53 alleles (Fig. 5B, subpanels h and i; Table 2). These results
indicate that the genetic basis for the differences between type
I and type II tumors includes the absence and presence, re-
FIG. 3. Tumor progression is associated with angiogenesis. Dysplastic CP (a) and tumor (b) sections from T121p53
1/2 mice were immuno-
stained using an antibody specific for CD31 to detect blood vessels (A). Each white bar represents 50 mm. Sections from brains of seven T121p53
1/2
mice at 5 to 7 weeks were analyzed. On the average, tumors contained larger vessels than did dysplastic tissue. Since even normal CP contains
numerous capillaries owing to its function as a blood-cerebrospinal fluid barrier, vessels larger than 200 mm2 were counted for a quantitative
comparison of the dysplastic and tumor vasculatures (Materials and Methods). By this analysis, tumors contained a significant increase in such
vessels (B).
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spectively, of p53 activity. Thus, p53 loss is associated with
progression to highly vascularized aggressive tumors. These
results further emphasize that the selective pressure for p53
inactivation is high. Moreover, since two functional alleles of
p53 are present in these mice, the strong correlation between
p53 inactivation and type I tumor progression indicates that
loss of the p53 pathway, likely of p53 itself, is the major rate-
limiting step to tumor progression (see Discussion). Further-
more, since p53 inactivation is associated with tumor progres-
sion rather than simply faster-growing dysplastic masses, p53
inactivation must contribute to tumorigenesis by mechanisms
in addition to apoptosis modulation.
Does p53 inactivation during tumor progression cause ge-
netic instability? A widely held hypothesis is that loss of p53
FIG. 4. Frequency and timing of tumor progression (A) and p53 inactivation (B) in T121p53
1/2 and T121p53
1/1 mice. (A) Before 6 weeks of
age, the CP of all T121p53
1/2 mice was dysplastic with no evidence of tumor progression. From 6 to 8 weeks, 95% of T121p53
1/2 mice developed
small focal tumors. From 9 to 14 weeks, these solid tumors rapidly increased in size (up to .100 mm3) and became life threatening. Tumor
progression occurred later and with a lower frequency in T121p53
1/1 mice. Only dysplasia was observed in most mice younger than 15 weeks. Focal
development of two distinct morphologies could first be observed in mice at 6 to 14 weeks. Ten percent of focal tumors were morphologically
indistinguishable from those developing in T121p53
1/2 mice (type I tumors), while 25% of tumors appeared distinct (type II [Fig. 2]). Beyond 25
weeks, 38% of mice had developed type I tumors and 59% had developed type II tumors. (B) Inactivation of p53 was detected by in situ detection
of p21 transcripts and/or by gene loss using PCR analysis as indicated (Fig. 5). More than 90% of T121p53
1/2 terminal tumors showed loss of the
wild-type p53 allele. Terminal tumors that did not demonstrate p53 LOH as well as early focal tumors (6 to 8 weeks) showed functional loss of
p53 based on loss of p21 expression. One-hundred-percent correlation of p53 inactivation with tumor progression indicates that p53 inactivation
is likely the facilitating event. In T121p53
1/1 mice, all type I tumors, but none of the type II tumors, showed loss of p53 function. All three terminal
type I tumors further analyzed by quantitative PCR showed a corresponding loss of at least one p53 allele, while the three type II tumors analyzed
retained both copies (real-time PCR data are presented in Table 2 and are not depicted in the histogram).
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function results in genomic instability and therefore could con-
tribute to tumor progression by facilitating the propagation of
genetic alterations. Although p53-deficient tumors and cell
lines often contain genetic aberrations (almost exclusively an-
euploidy), whether loss of p53 is a direct cause of genetic
instability is unknown (34). If inactivation of p53 function in
TgT121p53
1/2 CP results in genetic instability that facilitates
clonal tumor progression, such changes should be detectable in
tumors. To determine whether this is the case, we analyzed
TgT121p53
1/2 terminal tumors by CGH. In CGH, fluorescent-
ly labeled normal and tumor DNAs are competitively hybrid-
ized to normal metaphase chromosomes to assess genome-
FIG. 5. p53 is inactivated in all T121p53
1/2 and T121p53
2/2 type I tumors. (A) Genomic DNAs from TgT121p53
1/2 terminal tumors (lanes 1
to 11) and TgT121p53
1/2 tail DNA (“C,” lane 12) were analyzed by semiquantitative PCR to detect null (upper band) and wild-type (WT; lower
band) p53 alleles (see Materials and Methods). Samples shown are representative of 34 tumors analyzed. The signal from the wild-type p53 allele
is selectively reduced in all but one tumor (lane 9) relative to the upper band (the p53 null allele). The normalized intensity ratios of wild-type to
null alleles are listed under corresponding lanes. L (loss) and R (retention) were determined by using the arbitrary threshold (see Materials and
Methods). A total of 32 of 34 tumors analyzed in this fashion had lost the wild-type p53 allele (Fig. 4B). (B) Functional assessment of p53 by in
situ hybridization analysis of p21 transcript levels. p21 expression in CP is an indicator of p53 function. p21 transcripts are undetectable in
nontransgenic CP (a). p21 is induced upon activation of p53 by T121 (b). p21 expression is fully p53 dependent since it is absent in TgT121p53
2/2
CP (c). Functional assessment of p53 in TgT121p53
1/2 (d) or TgT121p53
1/1 (f) CP tissue shows that p21 expression (p53 activity) is absent in type
I tumor nodules but present in surrounding dysplastic CP (e and g). Type II tumors (h) retain p21 expression (i). Subpanels d, f, and h show
hematoxylin and eosin staining as viewed by bright-field microscopy. Subpanels e, g, and i show in situ hybridization with an antisense p21 RNA
probe viewed by dark-field microscopy. No signal was detectable using the sense probe (data not shown). Each bar represents 200 mm. The fre-
quency and timing of p53 inactivation for all samples analyzed are graphed in Fig. 4. non Tg, nontransgenic; br, brain tissue; tu, tumor; dy, dysplasia.
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wide copy number changes. With a resolution of approximately
10 Mb, CGH readily detects aneuploidy as well as partial
chromosome gains and losses (19).
Sixteen TgT121p53
1/2 terminal tumors were analyzed by
CGH (Fig. 6A and B). Normal tail DNA was used as a negative
control, while previously karyotyped aneuploid thymic lym-
phoma DNA was used as a positive control. A sex-mismatched
DNA mixture was also used as an internal control for copy
number changes. As anticipated based on the p53 LOH results
described above, most tumors (14 of 16) showed complete or
partial loss of a single copy of chromosome 11 (the location of
the p53 gene) (Table 3). Surprisingly, chromosome 11 loss was
the only aberration detected in any of the 16 tumors analyzed.
We also performed CGH analysis on six terminal TgT121
p531/1 tumors. Four tumors harbored no detectable changes.
These tumors were not characterized histologically and could
have possessed either type I or type II characteristics. Two
tumors showed loss of chromosome 11 and were presumably
type I tumors based on the association of p53 inactivation with
these tumors as described above. Both tumors also harbored
two to four additional changes (Fig. 6B; Table 3). Since type I
TgT121p53
1/1 tumors appear after long latency likely due to
the need to inactivate two wild-type p53 alleles, it is possible
that events leading to these changes preceded p53 inactiva-
tion in these tumors. This explanation would account for
the difference in the level of chromosome changes between
TgT121p53
1/1 and TgT121p53
1/2 tumors that have undergone
p53 inactivation. Four TgT121p53
2/2 CP masses were also an-
alyzed and shown to contain no detectable chromosomal losses
or gains (Table 3). A binomial statistical test comparing these
results to previous CGH studies with p531/2 and p532/2 tu-
mors from other models (16, 64) indicates that the lack of
chromosomal instability in TgT121p53
2/2 CP is statistically sig-
nificant (P , 0.01). As a positive control for CGH studies,
thymic lymphomas known to be aneuploid by karyotype anal-
ysis (37) were analyzed by CGH and shown to contain numer-
ous copy number changes (Table 3). Since CGH detects only
unbalanced chromosomal gains or losses, it was a formal pos-
sibility that tumors were polyploid. To test this possibility,
tumor DNAs were analyzed by flow cytometry. The majority of
cells in all five TgT121p53
1/2 tumors analyzed were diploid
(Fig. 6C). These results indicate that, contrary to popular hy-
pothesis, p53 inactivation is not sufficient to cause chromo-
somal instability during tumor progression. Furthermore, the
lack of chromosomal instability in these tumors indicates that
p53 inactivation contributes to tumor progression by an as yet
unidentified mechanism(s).
DISCUSSION
High selection for p53 inactivation during tumor evolution.
The data presented here show that there is immense selective
pressure for p53 inactivation during the natural evolution of
epithelial tumors initiated by inactivation of the pRb pathway.
Progression from dysplasia to solid aggressive tumors occurs in
100% of TgT121p53
1/2 mice, and all of these tumors have
inactivated p53. Even more indicative of the high pressure for
p53 inactivation was that 38% of TgT121p53
1/1 tumors in-
activated p53 function. Moreover, p53 was nonfunctional in
100% of type I tumors arising in this background. In TgT121
p531/2 tissue, where only a single allele loss is required for p53
inactivation, 95% of the progressed tumors had selectively lost
the wild-type p53 allele; the remaining tumors inactivated p53
by some other mechanism. Tumors that did not show p53 gene
loss, and all type I tumors from TgT121p53
1/1 mice, had lost
p53-dependent activation of p21 transcription. Thus, since p21
activation is immediately downstream of p53, no tumors inac-
tivated events downstream of p53. Furthermore, real-time
PCR analysis indicated that even p531/1 tumors had lost at
least one p53 allele, suggesting that p53 is the target for inac-
tivation and thus the rate-limiting step in tumor progression.
This indicates that there is no single linear pathway upstream
or downstream of p53 that is responsible for tumor suppres-
sion. Consistent with this observation, loss of p53 is associated
with tumor progression, rather than just rapid tissue growth,
implying that multiple p53-dependent mechanisms are respon-
sible for overall tumor suppression. While p53-mediated apo-
ptosis significantly slows dysplastic tissue growth and likely
accounts for the high selective pressure for p53 inactivation,
other p53 functions appear to suppress tumor progression (see
model in Fig. 1B).
By CGH analysis, we found that partial or complete loss of
a single copy of chromosome 11 occurred with a high fre-
quency to facilitate p53 inactivation in TgT121p53
1/2 tumors.
We considered the possibility that hemizygosity of other tumor
suppressors located on this chromosome could contribute to
tumor progression. However, two observations indicate that
this is not the case. First, some TgT121p53
1/2 tumors with
identical characteristics of progression did not lose chromo-
some 11 (Tables 2 and 3). Second, we have induced morpho-












1 Tail p531/1 1.0 4 2
2 Tail p531/2 0.33 6 0.24 4 1
3 Tail p531/2 0.21 6 0.02 2 1
4 Tumor (I) TgT121p53
1/2 0.17 6 0.05 4 1c
5 Tumor (I) TgT121p53
1/2 0.11 6 0.04 2 0
6 Tumor (I) TgT121p53
1/1 0.17 6 0.01 2 1d
7 Tumor (I) TgT121p53
1/1 0.48 6 0.14 2 1
8 Tumor (I) TgT121p53
1/1 0.14 6 0.01 2 0d
9 Tumor (II) TgT121p53
1/1 0.73 6 0.02 2 2
10 Tumor (II) TgT121p53
1/1 1.21 6 0.62 2 2
11 Tumor (II) TgT121p53
1/1 1.56 6 0.69 3 2
a Real-time PCR was performed to determine the status of the wild-type p53
alleles in TgT121p531/1 terminal tumors (see Materials and Methods). Among
six TgT121p531/1 tumors, all three type I tumors showed loss of at least one
wild-type p53 allele while all three type II tumors retained both wild-type alleles.
Two TgT121p531/2 tumors shown to have lost the wild-type p53 allele by allele-
specific PCR and CGH were used as controls.
b DDCt 5 [sample Ct(p53) 2 sample Ct(b-actin)] 2 [p531/1 control Ct(p53) 2
p531/1 control Ct(b-actin)], where Ct is the number of cycles required to reach a
threshold based on linear amplification (see Materials and Methods). Analysis of
standard samples indicated that copy numbers of 2, 1, and 0 are indicated by
22DDCt values of .0.6, between 0.15 and 0.6, and ,0.15, respectively.
c Although the value obtained here indicates detection of a wild-type allele in
this TgT121p531/2 tumor, this is likely due to the contamination of nontumor
tissue in the dissection procedure. Previous conventional PCR analysis and CGH
all showed that tumor 4 had p53 LOH.
d The 22DDCt value for tumors 6 and 8 that arose in mice with two wild-type
alleles is near the low end of the single-copy range. Further analysis will be
required to determine with certainty whether one or both wild-type alleles are
absent in these tumors. However, there is clearly loss of at least one allele.
VOL. 21, 2001 p53 INACTIVATION FACILITATES BRAIN TUMOR PROGRESSION 6025
FIG. 6. Chromosomal stability in p53-deficient tumors. (A) DAPI-stained metaphase chromosomes from normal mouse embryonic fibroblasts
are shown, with chromosomes 11 and X indicated (left). A composite digital image from CGH analysis of a representative TgT121p53
1/2 terminal
tumor is shown on the right. Tumor DNA (fluorescein isothiocyanate, green) and normal tail DNA (Alex-568, red) were hybridized to the
metaphase spread shown in the left panel. Relative green regions indicate increased copy numbers in the tumor, while red regions indicate
decreased copy numbers. The centromeres appear blue because repeated satellite sequences were blocked with unlabeled mouse Cot-1 DNA. This
tumor sample shows loss of chromosome 11. Apparent gain of the X chromosome serves as an internal control; tumor DNA was derived from a
female mouse, and normal DNA was from a male mouse. (B) Summary of CGH analysis of 14 TgT121p53
1/2 and 6 TgT121p53
1/1 tumors. Each
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logically identical tumors by focal transgenic expression of
full-length SV40 T antigen (11, 63). Since p53 is inactivated by
T antigen in this case, there is no selective pressure for p53
gene loss in these tumors. Indeed, by CGH these tumors
showed no loss of chromosome 11 (data not shown). Thus, p53
inactivation appears to be the critical event causing tumor
progression
Together with previous studies of p53 LOH in mouse tumor
models (40), the study presented here indicates that the selec-
tive pressure for p53 inactivation may vary with the cell type,
likely reflecting distinct mechanisms of p53 tumor suppression
or the tissue-specific presence of alternate tumor suppression
pathways. Pituitary and thyroid tumors of Rb1/2p531/2 mice
undergo Rb loss at a high frequency but rarely lose the wild-
type p53 allele (71). In addition to the cell type difference
between these studies, tumors in the present study were initi-
ated by inactivation of all three pRb-related proteins. Thus, the
difference in selective pressure for p53 inactivation could re-
flect cell type or mechanistic differences. In a study of lympho-
mas and sarcomas developing in p531/2 mice, the frequency
of p53 LOH was 15 to 50%, depending on the age of tumor-
bearing mice (64). In that study, p53 expressed in tumors with-
out LOH appeared to be functional in that it was inducible
by irradiation and was able to bind DNA specifically. The
frequency of p53 LOH in mammary tumors arising in Wnt-
1p531/2 mice was also about 50% (16), and in a chemically
induced skin tumor model, p53 LOH occurred in 64% of
carcinomas (8). A study of salivary and mammary tumors aris-
ing in the same MMTV-ras/p531/2 strain of mice offers a clear
demonstration of tissue-specific p53 LOH (29). While 10 of 10
salivary tumors lost the wild-type p53 allele, all 7 mammary
tumors analyzed retained the locus. Furthermore, by compar-
ing this study of mammary tumors (0% p53 LOH) to the study
with Wnt-1 mice (50% p53 LOH), it is clear that the selective
pressure for p53 inactivation appears to be influenced by the
preceding oncogenic event in addition to the tissue type. In-
deed, the frequency of p53 LOH in mammary tumors from
Brca1ko/cop531/2 mice was 80% (72). With the exception of
the analysis of p531/2 lymphomas and sarcomas, these studies
did not address whether p53 function was intact in the tumors
that retained a wild-type allele and thus represent a minimum
estimate of p53 inactivation.
When evaluating the impact of p53 inactivation on tumor
progression, it is important to examine the morphological evo-
lution of the tumor and its correlation with p53 inactivation. As
we observed with TgT121p53
1/1 mice, tumors may progress to
multiple grades within the same genotype. In this model, in-
activation of p53 correlated precisely with the development
of characteristic carcinomas, while slower-growing tumors
of distinct morphology retained p53 function. In most previous
studies, the relationship between p53 status and histologic
grade was not assessed. However, in the Wnt-1 mammary and
MMTV-ras mammary and salivary tumors described above,
p53 inactivation also correlated with a higher histologic grade.
In our studies, the perfect correlation between p53 inactiva-
tion and aggressive CP tumor progression indicates that p53
inactivation is a highly selected event and may be sufficient for
progression. In all other models analyzed thus far, the basis of
selective pressure for p53 inactivation is unknown. In dysplastic
CP, p53 is clearly required for apoptosis, such that cells that
inactivate other tumor suppression pathways but retain p53
would still undergo cell death. Thus, if apoptosis is not an
element of p53 tumor suppression in a given cell type, a more
random distribution of p53 inactivation may be observed.
p53 inactivation, genomic instability, and tumor progres-
sion. A common hypothesis for p53 tumor suppression is that
p53 prevents genetic instability. Based on this idea, we tested
whether CP tumor progression after p53 inactivation was fa-
cilitated by the accumulation of chromosomal abnormalities.
Aneuploidy is observed in p532/2 hematopoietic cells (6, 21),
in p53-deficient Li-Fraumeni syndrome (4) and mouse (24, 62)
fibroblasts, and in mouse thymic lymphomas induced by p53
deficiency (37, 64). However, TgT121p53
1/2 CP tumors were
diploid and showed partial or complete loss of a single copy of
chromosome 11 as the only detectable chromosomal aberra-
tion. The mouse p53 gene is located on chromosome 11, and
thus, its loss represents the selected causal event for tumor
progression. Hence, in brain epithelium p53 inactivation can
contribute to tumor progression by mechanisms other than the
induction of chromosomal instability.
Although loss of p53 function has been associated with ge-
TABLE 3. Comparative genomic hybridization analysis
of tumor DNAsa
Tumor type No. of tumors Chromosomal change(s)
TgT121p53





1/1 CP 1 dec11 (A1-B4); dec18 (A2-E4)
1 dec11 (A1-B3); dec1 (A2-B2);
dec8 (E3-H5); dec19 (B-D3)
4 None
TgT121p53
2/2 CP 4 None
TgTDN TL 1 inc4; inc5; inc10; inc15 (D1-F3)
1 inc4 (A5-E2); inc5; inc10; inc15
(A2-F3)
a Chromosomal changes are indicated as “dec” for DNA copy number de-
creases and “inc” for increases, followed by the affected mouse chromosome
numbers or subchromosomal regions. For TgT121p531/2 CP tumors, where in-
dicated the signal intensity was consistent with the loss of a single copy of
chromosome 11. TgTDN mice develop thymic lymphoma as a result of expressing
the SV40 T-antigen mutant dl1135, thus inactivating p53, in thymocytes. TL,
thymic lymphoma.
bar to the left of a depicted chromosome represents DNA copy number losses at the corresponding regions in a single tumor; no gains were
detected. Signal intensities were consistent with loss of a single copy. Red bars represent TgT121p53
1/2 tumors, and blue bars represent
TgT121p53
1/1 tumors. Chromosomes were identified by DAPI banding. Black bands in the chromosome diagrams represent the observed DAPI
staining pattern. (C) CP tumor cells from five TgT121 p53
1/2 mice were analyzed by propidium iodide staining and fluorescence-activated cell
sorting analysis for DNA content. More than 90% of cells in all five tumors are diploid.
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netic instability in numerous studies, there has been no direct
proof that p53 inactivation is sufficient to cause genetic insta-
bility or that such a function facilitates tumorigenesis in the
absence of other changes. In some mouse cancer models, tu-
mors that develop in the absence of p53 become aneuploid.
For example, CGH analysis of Wnt-1p531/2 terminal mam-
mary tumors showed that tumors with p53 LOH contained
more chromosomal changes (4.3 changes per tumor) than did
those without p53 LOH (1 change per tumor) (16). A similar
observation was made for p531/2 thymic lymphomas and sar-
comas, where tumors with p53 LOH contained an average of
5.6 changes per tumor compared to an average of 1 change
without p53 LOH (64). Likewise, mammary and salivary tu-
mors induced by MMTV-ras were largely diploid in the pres-
ence of p53 but aneuploid in its absence (29). These studies
indicate that loss of p53 function in tumors often correlates
with chromosomal instability.
Two alternative explanations could account for the appar-
ent differences in the level of genetic instability observed in
p53-deficient mouse tumors. One possibility is that these dif-
ferences reflect true tissue-specific differences in p53 tumor
suppression mechanisms. A second possibility is that p53 de-
ficiency is necessary but not sufficient to induce chromosomal
instability. Indeed, some studies of cultured p53-deficient cells
have indicated that p53 inactivation is not sufficient to drive
genetic instability (18, 49). Furthermore, in the study of Wnt-
1-induced mammary tumors, karyotype analysis indicated that
several p53-deficient tumors had nearly diploid profiles, similar
to those of p53 wild-type tumors, indicating that p53 inactiva-
tion was insufficient to cause aneuploidy (16). This notion is
also supported by the observation that the rapidly dividing cells
of p53-deficient embryos are diploid. However, combined de-
ficiencies in Brca1 and p53 induce aneuploidy in these cells
(57). Thus, in previous studies, tumors that harbored numer-
ous chromosomal changes may have undergone causal stochas-
tic mutations in addition to p53 loss. In the previous studies,
tumors were analyzed after substantial growth, during which
such events could have occurred. Although the TgT121p53
1/2
CP tumors were from terminally ill mice, brain tumors are
limited in the extent of their growth due to adverse effects on
the host. To determine whether p53 inactivation alone can
facilitate genetic instability and to rule out the possibility that
secondary changes are responsible, tumors must be analyzed
for chromosomal instability at early stages post-p53 loss. It is
possible that analysis of the brain tumors in the present study
represents such an early assessment of the impact of p53 in-
activation.
Our study of p53 deficiency in an evolving tumor showed
that genomic instability resulting from p53 loss did not drive
epithelial tumor progression. In a recent study, the frequency
of epithelial tumors was significantly increased in p53-deficient
mice that had been propagated through several generations in
the absence of telomerase function (1). Furthermore, these
tumors show chromosome instability including end-to-end fu-
sion and aneuploidy. Since such epithelial tumors are not ob-
served in the absence of telomere shortening, these results
indicate that p53 deficiency is required to propagate chromo-
somal instability when driven by other mechanisms but is itself
not the driving force. This mechanism also appears to be op-
erative in mouse lymphomas caused by a truncation of Brca2
(33). In that study, p53 inactivation was shown to be required
to propagate the Brca2 mutant cells due to severe chromo-
somal aberrations caused by the Brca2 defect.
If not chromosomal instability, what facilitates CP tumor
progression? Although aneuploidy is the most common genetic
change observed in p53-deficient cells, it is possible that p53
inactivation results in a type of genetic instability that is unde-
tectable by CGH. Point mutations, small deletions, inversions
or amplifications, balanced translocations, and microsatellite
instability would all escape detection by CGH. Currently, there
is no convincing precedent for the association of p53 inactiva-
tion with such changes. Although some studies have suggested
that p53 affects base (45) and nucleotide (69) excision repair
activities in vitro, the point mutation frequency is normal in
p53-deficient cells, tissues, and thymic lymphomas (44, 55).
Future experiments to detect the incidence of small deletions-
amplifications-inversions in progressing TgT121p53
1/2 tumors
will be required to determine whether p53 inactivation causes
any form of genomic instability.
Another possibility is that yet other p53 functions suppress
tumor progression. For example, previous studies indicate that
p53 can regulate the expression of angiogenesis factors. In
cotransfection experiments, p53 can induce transcription of the
angiogenesis inhibitor thrombospondin 1 (12) and other po-
tential angiogenesis inhibitors such as maspin (75) and BAI1
(59) through p53-specific DNA binding elements. In addition,
the angiogenesis activator vascular endothelial growth factor is
induced in p53-deficient cells by an unknown mechanism (5,
51, 66, 74). Since we show here that angiogenesis is a feature of
CP tumor progression associated with p53 inactivation, we are
currently exploring the possibility that p53 inactivation plays a
direct role in modulating the expression of angiogenesis fac-
tors, thus facilitating tumor progression.
In summary, p53 appears to suppress tumorigenesis in a
single tissue by multiple mechanisms. When tumor growth is
suppressed by p53-dependent apoptosis as in the CP tumors,
there is a high selective pressure for p53 inactivation. Inac-
tivation of p53 in turn facilitates tumor progression by a
mechanism that, surprisingly, does not include the induction of
chromosomal instability. These studies underscore the com-
plexity of p53 tumor suppression and the need to understand
the mechanisms in the context of natural selective pressures
occurring during tumor evolution in vivo.
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